Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Price Target at $50.42

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been given a consensus rating of “Buy” by the thirteen analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $50.42.

Several equities analysts have recently commented on the company. Chardan Capital reaffirmed a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Royal Bank of Canada started coverage on Dyne Therapeutics in a report on Tuesday, November 26th. They set an “outperform” rating and a $45.00 target price for the company. Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Finally, StockNews.com lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th.

Dyne Therapeutics Price Performance

DYN stock opened at $23.56 on Monday. Dyne Therapeutics has a one year low of $12.33 and a one year high of $47.45. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of -6.62 and a beta of 1.09. The company has a fifty day moving average price of $28.02 and a two-hundred day moving average price of $34.54.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Research analysts anticipate that Dyne Therapeutics will post -3.45 EPS for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 782 shares of the stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $33.10, for a total value of $25,884.20. Following the completion of the transaction, the director now owns 15,962 shares of the company’s stock, valued at approximately $528,342.20. This represents a 4.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $65,632.08. Following the sale, the insider now directly owns 201,685 shares in the company, valued at $5,671,382.20. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 44,742 shares of company stock worth $1,443,246 over the last three months. Corporate insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. FMR LLC increased its stake in shares of Dyne Therapeutics by 69.7% in the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after buying an additional 3,707,734 shares during the period. RTW Investments LP grew its holdings in Dyne Therapeutics by 6.8% during the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after acquiring an additional 431,503 shares during the last quarter. Janus Henderson Group PLC increased its position in Dyne Therapeutics by 47.3% in the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock valued at $244,755,000 after acquiring an additional 2,189,339 shares during the period. RA Capital Management L.P. increased its position in Dyne Therapeutics by 5.5% in the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after acquiring an additional 331,940 shares during the period. Finally, State Street Corp raised its stake in shares of Dyne Therapeutics by 13.8% during the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after acquiring an additional 440,890 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.